In consideration of the ever-growing prevalence of obesity and insulin resistance, an increasing interest to the development of new experimental antineoplastic drugs—targeting IGF-1 and/or insulin signaling pathways—are being employed in clinical trials (14, 32). The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.